#China #Taizhou #China SXT Pharmaceuticals #SXTC

China SXT Pharmaceuticals Secures $12 Million Through Direct Offering

China SXT Pharmaceuticals Inc. (NASDAQ: SXTC), a leading player in the pharmaceutical industry, has made a significant move by announcing a registered direct offering worth $12 million. This is part of a strategic initiative to bolster its resources and expand its operational capabilities.

On October 8, 2026, the company revealed that it entered into a definitive agreement with select institutional investors for the sale of 8,000,000 Class A ordinary shares at a price of $1.50 per share. The arrangement also includes 8,000,000 warrants with the same exercise price, which are immediately exercisable and have a lifespan of one year from the date of issuance. Each warrant permits the acquisition of up to nine Class A shares under a zero cash exercise option, further enhancing the investment appeal for potential investors.

The anticipated gross proceeds from this operation are approximately $12 million, expected to provide critical financial reserves for the company after settling the placement agent fees and other associated expenses. Notably, this offering grants investors the opportunity to purchase up to another $12 million of securities on similar terms within 30 days following the closing of the initial offering.

The target closing date for the offering is set for around October 9, 2026, pending customary closing conditions being met. Univest Securities, LLC is acting as the sole placement agent for this transaction, ensuring that the company navigates this fundraising effectively.

This direct offering is made in conjunction with a previously filed shelf registration statement on Form F-3 (File No. 333-291428), which has been effective since December 1, 2025. A detailed prospectus, supplementing the initial filing, will be available at the U.S. Securities and Exchange Commission (SEC) website, ensuring transparency for all stakeholders.

It’s essential to note that this announcement does not constitute an offer to sell or solicit an offer to buy securities in jurisdictions where such actions might breach local laws prior to obtaining proper registration or qualification.

A Closer Look at China SXT Pharmaceuticals Inc.

Founded in 2005 and based in Taizhou City, Jiangsu Province, China, SXT Pharmaceuticals has positioned itself as an innovative force in the pharmaceutical realm. The company's focus lies in the research, development, production, marketing, and sale of traditional Chinese medicine pieces. These products represent a modern approach to traditional healing, emphasizing the immense potential of traditional herbal resources supplemented by contemporary manufacturing practices.

With the influx of this new capital, SXT Pharmaceuticals is poised to enhance its market presence, potentially expanding its product range and research initiatives. The investment can significantly impact its long-term strategic goals, contributing to the company’s growth trajectory and market competitiveness.

The implications of such financial maneuvers could usher in a new era for the company, as it seeks to capitalize on the growing demand for herbal medicines and alternative treatment options in both domestic and international markets.

In a forward-looking statement, the company expressed confidence in the anticipated outcomes of this offering, stating that they believe the proceeds will enable further development and innovative research initiatives. However, the company also cautioned that actual results may differ from expectations due to various risks and uncertainties that might arise in the future.

As the pharmaceutical landscape continues to evolve, China SXT Pharmaceuticals Inc. remains committed to its mission, aiming to provide quality healthcare solutions while navigating the complexities of financial growth and market demands. With this latest financial strategy, the company appears well-prepared to tackle forthcoming challenges and explore new opportunities for expansion and innovation.